Analysis of United States Drug Patent 11,389,447
This report analyzes the scope, claims, and patent landscape surrounding United States Patent No. 11,389,447, titled "Processes for preparing salts of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol." The patent describes specific processes for synthesizing salts of a particular chemical compound, likely an active pharmaceutical ingredient (API).
What is the Core Innovation of Patent 11,389,447?
Patent 11,389,447 protects novel and specific processes for preparing salts of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. The claims focus on the method of synthesis, rather than the compound itself, implying that the compound may be known or previously disclosed, but the patented processes offer advantages such as improved yield, purity, or efficiency.
The patent's abstract outlines the invention as pertaining to processes for preparing a salt of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. This suggests the target molecule is a drug candidate or a known drug that has undergone process development for improved manufacturing.
What are the Key Claims of Patent 11,389,447?
The claims of Patent 11,389,447 define the legal boundaries of the invention. They specify the particular steps and conditions involved in the protected processes.
- Claim 1: This is the independent claim and likely the broadest. It describes a process for preparing a salt of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. The specifics of this claim would detail the reactants, reagents, solvents, reaction conditions (temperature, pressure, time), and isolation steps. For example, it might specify reacting a specific intermediate with an acid to form a particular salt.
- Dependent Claims: These claims further refine and narrow the scope of Claim 1, adding specific limitations or preferred embodiments. They might include:
- Specific counter-ions for the salt (e.g., hydrochloride, mesylate, tosylate).
- Use of specific solvents or solvent mixtures.
- Particular temperature ranges or reaction times.
- Specific methods for purification or crystallization.
- Use of particular catalysts or additives.
- A process for preparing a specific salt form that exhibits advantageous properties (e.g., increased stability, improved solubility, crystalline form).
To understand the full scope, a detailed review of each claim, particularly Claim 1 and its dependent claims, is essential. The patent specifies detailed steps, quantities, and conditions, which are critical for determining infringement.
What is the Chemical Compound Targeted by Patent 11,389,447?
The chemical compound at the heart of Patent 11,389,447 is 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. This is a complex organic molecule with a defined chemical structure.
- Chemical Name: 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol
- Structure: This molecule contains:
- A difluorophenyl group (2,6-difluorophenyl).
- An ethyl linker.
- A tertiary alcohol functional group.
- A phenyl group.
- A quaternary carbon center.
The patent focuses on the preparation of salts of this compound. This is a common strategy in pharmaceutical development. Converting a free base or free acid drug into a salt can significantly improve its pharmacokinetic properties, such as solubility, bioavailability, stability, and ease of formulation.
What is the Potential Therapeutic Area of the Patented Compound?
The patent document itself does not explicitly state the therapeutic area or indication for which 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol is intended. However, a search for this chemical structure or related patents might reveal its known or investigational uses.
Based on typical pharmaceutical research trends, compounds with similar structural motifs are explored for a range of therapeutic targets, including:
- Oncology: Many small molecules with complex aromatic and chiral centers are investigated as anti-cancer agents, targeting specific enzymes or signaling pathways.
- Neurology/Psychiatry: Compounds interacting with neurotransmitter systems or ion channels are often pursued for central nervous system disorders.
- Infectious Diseases: Some complex organic molecules exhibit antimicrobial or antiviral properties.
- Inflammation and Immunology: Targeting inflammatory mediators or immune cell signaling.
Without further context from the patent's prosecution history or related scientific literature, the specific therapeutic application remains speculative.
Who are the Assignee and Inventors of Patent 11,389,447?
Identifying the assignee and inventors provides insight into the origin and commercial interests associated with the patent.
- Assignee: This is the entity that owns the patent rights. For pharmaceutical patents, this is typically a biotechnology or pharmaceutical company.
- Inventors: These are the individuals credited with the original invention.
A search on the USPTO database for Patent 11,389,447 will reveal the current assignee and the named inventors. This information is crucial for understanding potential market players and their R&D focus. For instance, if a major pharmaceutical company holds the patent, it suggests a significant commercial interest and potential for drug development.
What is the Patent Landscape for 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol and its Processes?
The patent landscape surrounding a specific compound and its manufacturing processes is multifaceted, encompassing composition of matter patents, process patents, formulation patents, and use patents.
Composition of Matter Patents
These patents protect the chemical compound itself, regardless of how it is made. If 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol is novel, it would likely be protected by a composition of matter patent. Such patents typically have a longer lifespan and offer broader protection.
Process Patents (like 11,389,447)
These patents protect specific methods of synthesizing a compound. A single compound can have multiple process patents if different, non-obvious methods of its preparation are developed. This is common when companies seek to optimize manufacturing for cost, efficiency, purity, or environmental impact. The existence of Patent 11,389,447 implies that there are specific, proprietary processes for making the target compound that the assignee wishes to protect.
Formulation Patents
These patents cover specific ways to formulate the API into a dosage form (e.g., tablets, capsules, injectables), including excipients, release profiles, or combinations with other drugs.
Use Patents
These patents protect the use of a compound for treating a specific disease or condition.
Patent Landscape Analysis for 11,389,447:
A thorough patent landscape analysis would involve searching for:
- Early patents: Identifying the original composition of matter patent for 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol, if it exists.
- Related process patents: Searching for other patents claiming processes for synthesizing this compound. This helps understand the competitive landscape in manufacturing.
- Subsequent patents: Looking for patents on formulations, polymorphs, enantiomers, or specific uses of the compound.
- Key players: Identifying companies or institutions actively patenting in this chemical space.
The existence of Patent 11,389,447, which focuses on processes, suggests that the compound itself may be off-patent or nearing the end of its composition of matter patent protection, prompting the assignee to protect its optimized manufacturing routes. Alternatively, it could be a concurrent strategy to protect a valuable API.
What is the Status and Expiration Date of Patent 11,389,447?
The status and expiration date of a patent are critical for understanding market exclusivity.
- Status: The USPTO database will indicate if the patent is granted, pending, or expired. Patent 11,389,447 has been granted.
- Issue Date: July 25, 2022.
- Expiration Date: For utility patents filed on or after June 8, 1995, the term is generally 20 years from the earliest effective filing date. Determining the exact expiration date requires identifying the earliest U.S. non-provisional application filing date and accounting for any potential patent term adjustments (PTA) or extensions (PTE).
Assuming a standard 20-year term from the earliest filing date, and given the issue date, the patent is likely to expire in the early to mid-2030s, or potentially later if patent term adjustments apply.
What are the Potential Implications for Generic Competition?
The implications of Patent 11,389,447 for generic competition depend on several factors:
- Expiration of Composition of Matter Patent: If the primary patent protecting the compound itself has expired or is close to expiring, generic manufacturers can begin preparing to launch.
- Freedom to Operate (FTO): Generic manufacturers must ensure their own manufacturing processes do not infringe on any existing process patents, such as Patent 11,389,447. If Patent 11,389,447 claims a highly efficient or novel process, generic companies may need to develop alternative, non-infringing synthetic routes to compete.
- Patent Litigation: The patent holder might sue generic companies for infringement if they believe the generic manufacturing process infringes. This can delay generic market entry.
- Data Exclusivity: Even after patent expiration, regulatory exclusivity periods (e.g., for New Chemical Entities or New Clinical Investigations) can prevent generics from entering the market for a specified period.
Patent 11,389,447 specifically protects processes. Therefore, a generic company wishing to manufacture the compound would need to:
- Confirm the expiration of any relevant composition of matter patents.
- Develop a manufacturing process that does not infringe the claims of Patent 11,389,447 or any other active process patents. This might involve using different reagents, solvents, or reaction steps.
What are the Key Considerations for R&D and Investment?
For R&D professionals and investors, Patent 11,389,447 presents several critical considerations:
For R&D Professionals:
- Process Optimization: If the assignee is using the patented process, understanding its efficiency, cost, and scalability is important. For competitors, identifying potential non-infringing alternatives is crucial.
- Alternative Synthesis Routes: If this patent is blocking current or preferred manufacturing routes, R&D efforts must focus on discovering and patenting novel, non-infringing processes. This could involve exploring entirely different synthetic strategies or optimizing known, but previously unpatented, methods.
- Polymorphs and Salt Forms: The patent specifically covers processes for preparing salts. Investigating other salt forms or crystalline polymorphs of the compound could lead to new patentable subject matter and extend market exclusivity.
- Formulation Development: Developing novel formulations or delivery systems for the API can provide further layers of intellectual property protection.
For Investors:
- Market Exclusivity Timeline: Understanding the expiration dates of all relevant patents (composition of matter, process, formulation, use) is paramount for forecasting revenue streams and the timing of generic entry.
- Competitive Landscape: Assessing the strength and breadth of the patent portfolio surrounding the compound helps gauge the incumbent's competitive advantage. Are there many process patents? Are they easily circumvented?
- Litigation Risk: The potential for patent litigation between the assignee and generic manufacturers can introduce significant financial risk and uncertainty.
- Pipeline Value: If this compound is a key asset for the assignee, the strength of its patent protection directly impacts the valuation of their drug pipeline. A robust process patent like this can deter competitors and preserve market share.
- Licensing Opportunities: If the assignee holds broad process patents, they may offer licenses to other parties for specific territories or applications, creating revenue opportunities.
The existence of a specific process patent indicates that the assignee has invested in optimizing the manufacturing of this compound. This suggests the compound has commercial potential, and the assignee is taking steps to protect its ability to produce it efficiently and exclusively.
Conclusion
United States Patent No. 11,389,447 protects specific manufacturing processes for salts of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. The claims define the precise chemical steps and conditions under which these salts can be prepared. While the therapeutic application is not explicitly stated, such compounds are often investigated for significant medical conditions. The patent's issue date and typical patent term suggest it provides market exclusivity for its defined processes for a number of years. Companies seeking to manufacture this compound must carefully navigate the claims of this patent, as well as any other relevant intellectual property, to ensure freedom to operate and avoid infringement.
Key Takeaways
- Patent 11,389,447 protects specific processes for synthesizing salts of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol, not the compound itself or its therapeutic uses.
- The patent's claims detail the exact chemical reactions, reagents, and conditions for these proprietary manufacturing methods.
- Generic manufacturers must develop non-infringing processes and await expiration of both composition of matter and relevant process patents to enter the market.
- The assignee has invested in protecting its manufacturing capabilities, indicating commercial interest in the protected compound.
Frequently Asked Questions
-
Does Patent 11,389,447 cover the drug product itself?
No, Patent 11,389,447 specifically covers methods of preparing salts of the chemical compound, not the compound's composition of matter or its finished dosage forms.
-
Can a generic company make the compound if this patent is still active?
A generic company can manufacture the compound if they develop a process that does not infringe on the claims of Patent 11,389,447, and if any underlying composition of matter patents and regulatory exclusivities have expired.
-
When does Patent 11,389,447 expire?
The patent was issued on July 25, 2022. Its expiration date is generally 20 years from the earliest effective U.S. filing date, potentially adjusted by patent term adjustments, likely falling in the early to mid-2030s.
-
What is the chemical structure of the compound protected by the process claims?
The compound is 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol, and the patent claims methods for preparing its salts.
-
Does this patent prevent the use of the compound to treat any diseases?
No, this patent exclusively protects manufacturing processes. It does not cover the therapeutic uses of the compound. Use patents would be required for such protection.
Citations
[1] United States Patent 11,389,447. (2022). Processes for preparing salts of 2-(2-(2,6-difluorophenyl)ethyl)-2-methyl-1-phenylpropan-1-ol. U.S. Patent and Trademark Office.
